Tetra Bio-Pharma Announces Outcome of its Meeting with its …

OTTAWA, ONTARIO–(Marketwired – Nov 2, 2016) – Tetra Bio-Pharma Inc. (“TetraBio” or the “Company“) (CSE:TBP) through its subsidiary, PhytoPain Pharma Inc. (“PPP“), is pleased to announce that it held its Scientific and Clinical Advisory Board (“CAB“) meeting on October 29th. The CAB reviewed the development program of PPP’s inhalation cannabis product PPP001. PPP001 is a medical marijuana product that the company is developing as a prescription controlled drug for inhalation using a fully assembled titanium pipe.

The Board, which is comprised of experts in clinical research, pain management as well as cancer, and neurological product drug development (ref: news release August 26, 2016), met to review and discuss the development program to date, the study design of the Phase I trial and the overall clinical development plan of PPP001. This included the exclusion and inclusion criteria of the proposed Phase

... read more at: http://sports.yahoo.com/news/tetra-bio-pharma-announces-outcome-170943998.html